

FANC
[Lot No.: UT359M]
**On the In vivo Human Skin Anti-wrinkle Efficacy
Evaluation of 0.10 μ M FANC**
FINAL REPORT

Client: GOLDRED NANOBIOTECH CO., LTD.

Testing Institution: SGS TAIWAN LTD.

Report No.: UB/2016/A1186

- Note:**
1. The content of this report is invalid if it is not presented as the entire report.
 2. Any unauthorized alteration, forgery or falsification of the content or appearance of this report is unlawful and offenders may be prosecuted to the fullest extent of the law.
 3. The results shown in this test report refer only to the article(s) tested.



TABLE OF CONTENTS

ADDRESS INFORMATION	3
INFORMATION FOR TEST ARTICLE.....	4
SIGNATURE OF STUDY PERSONNEL	5
PROCEDURE	8
RESULTS	9
REFERENCES.....	11



ADDRESS INFORMATION

Testing Institution

Name: SGS TAIWAN LTD.

Address: No. 38, Wuquan 7th Rd., New Taipei Industrial Park, Wugu Dist., New Taipei City 24890, Taiwan (R. O. C.)

Name: National Tainan Junior College of Nursing

Address: 78, Sec. 2, Minzu Rd., Tainan City 700, Taiwan, R.O.C.

Client / Sponsor

Name: GOLDRED NANOBIOTECH CO., LTD.

Address: 2F., No.68-1, Jilin Rd., Zhongli District, Taoyuan City 32062, Taiwan(R.O.C.)

INFORMATION FOR TEST ARTICLE

台灣檢驗科技股份有限公司

客戶資料與成分資料表

公司名稱/Sponsor company : 紅嬰生物科技股份有限公司
 公司地址/Sponsor address : 桃園縣中壢市文化里21鄰吉林路68-1號2樓
 測試件名稱/Name of test article : 亮金圍顏(FANC)
 包裝/Package : 2mL
 測試件外觀型態/External features : 液狀liquid
 顏色/color : 金黃色

主要成分/Major components :

Example	Ingredient Name(成分名)	CAS or CI Number	%
1	Formaldehyde 亮金圍顏(FANC)	50-00-0 NA	5.00% 132.2uM
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			

客戶簽章/日期 Sponsor signature/ date : _____

※ 上述所有資料是由客戶揭露並負責,且確定所提供的檢品是國內所允許製售化粧品,其配方及其濃度均合乎國內化粧品標準。(Above all information is disclosed by the sponsor. In addition, provided samples are allowed by domestic selling cosmetics. The formulation and concentration are all allowed in domestic cosmetic regulation.)




SIGNATURE OF STUDY PERSONNEL

On the In vivo Human Skin Anti-wrinkle Efficacy Evaluation of 0.10 μ M FANC FANC


Study Director:


Howard Kao / SGS Taiwan Ltd.


Date

Facility Manager:


Yuanmin Wen / SGS Taiwan Ltd.


Date

Study Duration: 2016.10.25~2017.01.23

Sample Photo:



Test Sample Handling:

According to client's request, test sample was prepared from 132.2 μ M FANC Solution, Formula as list in following table :

Ingredients \ Formula	0.10 μ M FANC Solution
132.2 μ M FANC Solution	0.0757 %
Water	99.9243 %

Panel Demographics

Number of subjects enrolled	20
Number of subjects completing study	20
Age Range	26-51
Sex	Male.....0 Female..... 20

Panel Composition:

20 Asian healthy subjects (age 26-51 years) were recruited for this study. The panel consisted of fair-skin individuals with Fitzpatrick Type II, III and IV. Subjects who will read, understand an informed consent document relating to the specific type of study they are subscribing. Subjects free of any dermatological or systemic disorder which would interfere with the results, at the discretion of the investigator. Skin responses will be evaluated by an IRV-3D.

Biophysical Instruments & Evaluation of Responses

Method	Claims	Instrument
Skin Wrinkle (cheek)	Reducing fine line & wrinkle; Anti-wrinkle	IRV-3D

IRV-3D:

IRV-3D offer a greater degree of clinical information on a wide range of skin conditions. Which possess extremely homogenous illumination of the face by 210 white light LEDs, without developing heat and a high resolution reflex camera (Canon EOS 700D) integrated with a special objective allow to take detailed facial photos.

PROCEDURE

Twenty Asian healthy volunteers are included in each evaluation, after giving their written consent. The clinical investigator assess that they are in good health and have no dermatological diseases around test areas. The products are applied at the rate of 2 mg/cm². The test product is applied twice a day for 28 days. Measurements are performed before first application and at 14th and 28th treatment day. Measurements will be carried out in a clean room (60 ± 5 % RH, 22 ± 2 °C). The difference between untreated and the treated area will be statistically evaluated.


RESULTS

Anti-wrinkle (cheek):

IRV-3D offer a greater degree of clinical information on a wide range of skin conditions.

Subject ID #	Before Patch	After 14h Patch	After 28h Patch
A01	40.6	38.9	38.5
A02	33.6	32.6	32.3
A03	40.9	43	42.3
A04	42.6	42	41.6
A05	52.9	52.9	52
A06	49.1	49.9	47
A07	48.6	45	43
A08	52.2	52.9	48
A09	67.2	67.3	66
A10	41.3	37.9	36
A11	46.7	48.9	45
A12	54.5	52	48
A13	48	43	42.5
A14	38	36	34
A15	53	52	51
A16	48	49	47
A17	43	42	39
A18	46	45	43
A19	38	36	36.5
A20	37	34	35.5
Mean	46.1	45.0	43.4
SD	7.8	8.4	7.7
RSD	17%	19%	18%
Spooled	Baseline	8.0579	7.747
t-value	Baseline	0.4113	1.0825
Probability	Baseline	0.6832	0.2859
Sig. Diff.	Baseline	No	No
Improvement	Baseline	2.3%	5.8%

0.10 μ M FANC Solution, Report No.: UB/2016/A1186



Result:

Throughout the Day 14 and Day 28 of anti-wrinkle examination of 20 Asian healthy subjects, 2.3% and 5.8% improvement were observed after treatment of 0.10 μ M FANC Solution in the treated site. Based on the study result the claims "Proven to reduce skin wrinkle" for test product are substantiated.

REFERENCES

1. *Product Test Guidelines for the Assessment of Human Skin Compatibility*, Colipa Guidelines, 1997.
2. S. A. Wissing and R.H. Muller, “*The influence of solid lipid nano-particles on skin hydration and visco-elasticity – in vivo study*”, *European J. Pharm. Biopharm.*, 56, 2003, 67-72
3. S. Vertuani, P. Ziosi, N. Solaroli and V. Buzzoni, “*Determination of antioxidant efficacy of cosmetic formulations by non-invasive measurements*”, *Skin Res. Tech.*, 9, 2003, 245-253
4. A. Barel, M Calomme, A. Timchenko and K. D. Paepe, “*Effect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photo-damaged skin*”, *Arch Dermatol. Res.*, 297, 2005, 147-153
5. H. B. Gladstone, S. L. Nguyen and R. Willams, “*Efficacy of hydroquinone cream (USP 4%) used alone or in combination with salicylic acid peels in improving photo-damage on the neck and upper chest*”, *Dermatol. Sur.*, 26(4), 2000, 333-337